Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemifloxacin.

M N Lowe1, H M Lamb

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 14, 2000
PubMed
Summary
This summary is machine-generated.

Gemifloxacin, a potent fluoroquinolone antibiotic, shows high efficacy against Streptococcus pneumoniae and atypical respiratory pathogens. Clinical trials indicate excellent bacteriological responses in treating chronic bronchitis and urinary tract infections with minimal adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Denileukin diftitox.

American journal of clinical dermatology·2001
Same author

Bexarotene.

American journal of clinical dermatology·2001
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Microbiology and Infectious Diseases
  • Pharmacology and Therapeutics

Background:

  • Gemifloxacin is a novel fluoroquinolone antibiotic.
  • It exhibits enhanced affinity for bacterial topoisomerase IV, crucial for DNA replication.
  • Understanding its spectrum of activity and clinical efficacy is essential for guiding therapeutic use.

Purpose of the Study:

  • To evaluate the in vitro antibacterial spectrum of gemifloxacin.
  • To assess the clinical efficacy and safety of gemifloxacin in treating respiratory and urinary tract infections.

Main Methods:

  • In vitro susceptibility testing against various bacterial pathogens, including Gram-positive, Gram-negative, and atypical organisms.
  • Phase II clinical trials evaluating oral gemifloxacin (320 mg/day) in patients with acute exacerbations of chronic bronchitis and uncomplicated urinary tract infections.

Related Experiment Videos

  • Monitoring of bacteriological response rates and adverse events.

    • Main Results:

    • Gemifloxacin demonstrated potent activity against Streptococcus pneumoniae, exceeding that of ciprofloxacin and moxifloxacin.
    • Excellent activity was observed against Haemophilus influenzae, Moraxella catarrhalis, and atypical respiratory pathogens (Legionella, Mycoplasma, Chlamydia spp.).
    • Phase II trials reported high bacteriological response rates: 94.7% for chronic bronchitis and 95% for urinary tract infections.
    • Common adverse events included nausea, abdominal pain, headache, and mild rash; phototoxicity potential was low.

    Conclusions:

    • Gemifloxacin possesses a broad spectrum of activity, particularly against key respiratory pathogens and atypical organisms.
    • It demonstrates significant clinical efficacy in treating acute exacerbations of chronic bronchitis and uncomplicated urinary tract infections.
    • Gemifloxacin offers a favorable safety profile with a low potential for phototoxicity.